A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu (trastuzumab deruxtecan) in March 2019 and datopotamab deruxtecan in July 2020, except ...

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.

As per several reports online, a scientist, Beata Halassy (49), recently successfully treated her own breast cancer by ...

Researchers found no significant differences in safety outcomes between trastuzumab biosimilars and the originator product across subgroups. Trastuzumab biosimilars have similar safety profiles as ...

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

Trastuzumab duocarmazine (T-Duo) improved progression-free survival to 7.0 months compared with 4.9 months with a physician’s choice in advanced human epidermal growth factor receptor 2 ...

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or ...

Drugs that target advanced breast cancer could help patients with a rare cancer that affects parts of the digestive system, a ...

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).